Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Nov 18, 2024
Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. It affects about 10 million people worldwide. The average age of onset for Parkinson’s disease is around 60; however, approximately 10-15% of patients experience early-onset PD before the age of 50. In 2023, there...
Read More...
Dec 30, 2022
Parkinson’s disease (PD) is a degenerative neurological condition primarily affecting middle-aged and older adults and is characterized by tremors, muscular rigidity, and slow, clumsy movement. It is connected to the brain’s basal ganglia atrophy and a lack of the neurotransmitter dopamine. Levodopa is considered a...
Read More...
Feb 25, 2022
Parkinson's disease (PD) is the second most prevalent neurogenerative disorder, with a growing global prevalence due to population aging. Despite increased awareness and significant research advancement, Parkinson’s disease treatment options include dopamine replacement therapy, symptomatic therapies that have sign...
Read More...
Dec 31, 2021
Parkinson's disease is a neurodegenerative disorder that affects predominately dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra. Parkinson's disease has four main symptoms such as tremor (trembling) in hands, arms, legs, jaw, or head, stiffness of the limbs and tru...
Read More...
Nov 11, 2019
Parkinson's disease prevalence is rising. According to a survey conducted by Parkinson.org, around one million people in the US will be living with Parkinson’s disease by the end of 2020. The number is shockingly high as the prevalence of multiple sclerosis combined with muscular dystrophy and Lou Gehrig’s dise...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper